Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phentolamine for CA-AKI Prevention in Complex PCI
NCT06286059Phase 3Recruiting
- Sponsor
- Helwan University
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of phentolamine in contrast-associated acute kidney injury (CA-AKI), sponsored by Helwan University. Started Mar 2024; status: recruiting.
02
Drugs
phentolamine
03
Conditions
contrast-associated acute kidney injury (CA-AKI)
Beyond the preview
Go deeper on NCT06286059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06286059.